Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5513083 | The Journal of Steroid Biochemistry and Molecular Biology | 2017 | 11 Pages |
â¢26-Hydroxy- and 24(or 25)-hydroxy-8-dehydrocholesterol identified in SLOS plasma.â¢Enhanced concentrations of 7β-hydroxy- and 7-oxo-cholesterol in SLOS plasma.â¢Free radical generated 3β,5α-dihydroxycholest-7-en-6-one found in SLOS plasma
Smith-Lemli-Opitz syndrome (SLOS) is a severe autosomal recessive disorder resulting from defects in the cholesterol synthesising enzyme 7-dehydrocholesterol reductase (Î7-sterol reductase, DHCR7, EC 1.3.1.21) leading to a build-up of the cholesterol precursor 7-dehydrocholesterol (7-DHC) in tissues and blood plasma. Although the underling enzyme deficiency associated with SLOS is clear there are likely to be multiple mechanisms responsible for SLOS pathology. In an effort to learn more of the aetiology of SLOS we have analysed plasma from SLOS patients to search for metabolites derived from 7-DHC which may be responsible for some of the pathology. We have identified a novel hydroxy-8-dehydrocholesterol, which is either 24- or 25-hydroxy-8-dehydrocholesterol and also the known metabolites 26-hydroxy-8-dehydrocholesterol, 4-hydroxy-7-dehydrocholesterol, 3β,5α-dihydroxycholest-7-en-6-one and 7α,8α-epoxycholesterol. None of these metabolites are detected in control plasma at quantifiable levels (0.5 ng/mL).
Graphical abstractDownload high-res image (52KB)Download full-size image